Dr. Jeffrey M. Clarke
Claim this profileDuke Cancer Institute
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
12 reported clinical trials
20 drugs studied
Area of expertise
1Lung Cancer
Stage IV
Stage III
chemotherapy
2Non-Small Cell Lung Cancer
Stage IV
chemotherapy
metastatic
Affiliated Hospitals
Clinical Trials Jeffrey M. Clarke is currently running
C-TIL051 + Anti-PD1 Therapy
for Lung Cancer
The goal of this Phase 1 clinical study is test tumor infiltrating lymphocytes (known as C-TIL051) with NKTR-255 and anti-PD1 therapy for subjects with refractory non-small cell lung cancer. The purpose of this study is to: 1. Test the safety and ability for subjects to tolerate the TIL therapy 2. Measure to see how the NSCLC responds to the TIL therapy Participants will be asked to: * Provide a tumor sample prior to the start of any treatment which will be used to make the C-TIL051. * Receive standard of care treatment until their lung cancer no longer responds * When necessary, the C-TIL051 will be manufactured by the sponsor and sent back to the site * Subject will then receive chemotherapy (called lymphodepletion) for 3 days followed by 2 days of rest * C-TIL051 will then be infused on day 0 followed by NKTR-255 (IL-15) about 12 to 24 hours later * Pembrolizumab will be administered every 3 weeks for up to 2 years NKTR-255 is a novel polymer-conjugated human IL-15 receptor agonist molecule designed to increase the proliferation and survival of memory CD8+ T cells and enhance the formation of long-term immunological memory which may lead to sustained anti-cancer immune response. The combination of NKTR 255 and TIL's could improve proliferation and persistence of cellular therapies leading to enhanced anti-tumor activity.
Recruiting1 award Phase 110 criteria
Pre-Surgery Immunotherapy
for Mesothelioma
This trial tests if giving immunotherapy drugs can better control disease in patients with a specific type of mesothelioma. The drugs help the immune system attack cancer cells, which may stop the cancer from growing and spreading.
Recruiting1 award Phase 227 criteria
More about Jeffrey M. Clarke
Clinical Trial Related3 years of experience running clinical trials · Led 12 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Jeffrey M. Clarke has experience with
- Pembrolizumab
- GT103
- Nivolumab
- Durvalumab
- Tremelimumab
- Platinum Cisplatin Or Carboplatin And Pemetrexed Chemotherapy
Breakdown of trials Jeffrey M. Clarke has run
Lung Cancer
Non-Small Cell Lung Cancer
Pancreatic Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Jeffrey M. Clarke specialize in?
Jeffrey M. Clarke focuses on Lung Cancer and Non-Small Cell Lung Cancer. In particular, much of their work with Lung Cancer has involved Stage IV patients, or patients who are Stage III.
Is Jeffrey M. Clarke currently recruiting for clinical trials?
Yes, Jeffrey M. Clarke is currently recruiting for 3 clinical trials in Durham North Carolina. If you're interested in participating, you should apply.
Are there any treatments that Jeffrey M. Clarke has studied deeply?
Yes, Jeffrey M. Clarke has studied treatments such as Pembrolizumab, GT103, Nivolumab.
What is the best way to schedule an appointment with Jeffrey M. Clarke?
Apply for one of the trials that Jeffrey M. Clarke is conducting.
What is the office address of Jeffrey M. Clarke?
The office of Jeffrey M. Clarke is located at: Duke Cancer Institute, Durham, North Carolina 27710 United States. This is the address for their practice at the Duke Cancer Institute.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.